Supplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Résumé fourni par la source
RPSFTM-adjusted overall survival by initial treatment modality. RPSFTM-adjusted overall survival. The observed CAR T-first curve (solid dark blue) is compared with the observed BsAb-first curve (dashed crimson) and the RPSFTM-adjusted BsAb-first curve (solid orange). The adjusted curve represents the counterfactual survival of BsAb-first patients had no treatment switching to CAR T occurred, estimated using rank-preserving structural failure time modeling with g-estimation. Number at risk tables are shown below each panel. All estimates are descriptive and should be interpreted in the context of non-randomized treatment allocation and the assumptions of the RPSFTM framework.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Supplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
- Date Crossref
- 03/09/2026
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.